news_6

First-in-Class GPR119 Agonist of Dong-A ST, DA-1241 Improved Glucose Control in Patients With Type 2 Diabetes in US Phase 1b Study

SEOUL, South Korea--(BUSINESS WIRE)--#ClinicalDevelopment--Dong-A ST (KRX: 170900) today announced that it successfully completed the proof-of-concept study for ‘DA-1241,’ an investigational...